Intellia Therapeutics Shares Rally on Major Institutional Buying

The gene-editing specialist Intellia Therapeutics has started 2026 with significant momentum, fueled by substantial and concentrated buying from a prominent institutional investor. ARK Invest, the firm led by Cathie Wood, has been aggressively adding to its stake in the company this week, providing notable support for the share price.

A clear trend reversal is now evident when comparing recent performance with the previous year. After a challenging 2025 that saw shares decline by approximately 23%, Intellia's stock has surged more than 32% since the start of 2026. This establishes a pronounced upward trend, largely underpinned by renewed confidence from major investors.

The market's reaction to ARK's recent purchases was immediate and positive. Following the disclosure of the latest transactions, Intellia's equity gained over 2% in after-hours trading. On a weekly basis, the stock is poised to deliver its strongest performance since last October.

Should investors sell immediately? Or is it worth buying Intellia Therapeutics?

ARK Invest Concentrates Its Position

Recent trade disclosures from ARK Invest reveal a clear strategy of accumulation. Notably, on Thursday, Intellia was the sole company in which ARK deployed capital, signaling a high-conviction focus on this specific holding.

The firm executed purchases across several of its exchange-traded funds in multiple tranches over just a few days. A summary of the reported activity shows:

• Thursday's Purchases: 56,769 shares acquired for a total value of $682,363.
• Fund Allocation: 48,178 shares were added to the ARKK ETF, with 8,591 shares going into the ARKG ETF.
• Earlier Activity: This follows the acquisition of 40,067 shares on Tuesday and a purchase of 99,292 shares on Monday.

These moves bring ARK's total accumulation for the period to well over 190,000 shares. The sustained demand from such a visible institutional player is having a tangible impact on market sentiment and trading dynamics for Intellia Therapeutics.